Trials / Completed
CompletedNCT01626456
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 478 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 9072, Low | IM injection, given monthly |
| DRUG | ALKS 9072, High | IM injection, given monthly |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2012-06-22
- Last updated
- 2018-09-25
- Results posted
- 2016-10-27
Locations
82 sites across 8 countries: United States, Bulgaria, Malaysia, Philippines, Romania, Russia, South Korea, Ukraine
Source: ClinicalTrials.gov record NCT01626456. Inclusion in this directory is not an endorsement.